UroGen Pharma Ltd.

General Information

We are a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. We have an innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Our lead product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is currently used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

Employees: 29
Founded: 2004
Contact Information
Address 9 Ha’Ta’asiya Street, Ra’anana 4365007, Israel
Phone Number +972 (9) 770-7601
Web Address http://www.urogen.com
View Prospectus: UroGen Pharma Ltd.
Financial Information
Market Cap $161.6mil
Revenues $17.5 mil (last 12 months)
Net Income $-1.9 mil (last 12 months)
IPO Profile
Symbol URGN
Exchange NASDAQ
Shares (millions): 4.5
Price range $13.00 - $13.00
Est. $ Volume $58.2 mil
Manager / Joint Managers Jefferies/ Cowen and Company
CO-Managers Raymond James/ Oppenheimer
Expected To Trade: 5/4/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change